Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Dr. Christopher's
WARNING LETTER
•Dr. Christopher's•December 31, 2010

FDA WARNING_LETTER - Dr. Christopher's - December 31, 2010

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Dr. Christopher's
Record Details

The FDA issued a Warning Letter to Josh Scott regarding products promoted on www.drchristophers.com and www.herbshopconnection.com. An FDA review in December 2010 found that products including "Bilberry Eye Capsule," "Cayenne Pepper Extract," and "Hawthorn Berry Heart Syrup" are promoted for conditions that classify them as drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act).

The therapeutic claims on the websites, such as preventing glaucoma, treating cancer, or addressing heart disease, establish these products as drugs intended for diagnosis, cure, mitigation, treatment, or prevention of disease. These claims violate the Act.

Furthermore, these products are considered "new drugs" under section 201(p) of the Act because they are not generally recognized as safe and effective for their claimed uses. Marketing new drugs without prior FDA approval, as required by section 505(a), is illegal.

Additionally, the products are misbranded under section 502(f)(1) of the Act because they are offered for conditions not amenable to self-diagnosis and treatment by laypersons, meaning adequate directions for safe use cannot be provided.

The FDA requires prompt corrective action within fifteen working days, including written notification of steps taken to correct violations and prevent recurrence. Failure to comply may result in regulatory actions such as seizure or injunction.

Company
Dr. Christopher's
Inspection Date
December 31, 2010
Product Type
Drugs
Office
Denver District Office
People
  • Harry T. Warwick
  • Robert Scott
Open in Dashboard

ID · 25bf7924-66e5-4736-8a29-a643d49ff1cc

Violation Codes6
21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(p)21.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 U.S.C. 33221 U.S.C. 334

Full citation text and observation details available on the Dashboard.

KeyPedia
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.